In The UK Why Do We Have 140 licensed Dermal Fillers Whereas there are only 25 in the USA ?

140 Fillers or 25? What the Difference Between CE Marking and FDA Approval Actually Means for Patients and Practitioners

market has over 140 CE-marked dermal . The United States has fewer than 25 FDA-approved . That disparity is not a coincidence — and understanding why it exists has genuine clinical .

Over 140 dermal fillers are currently licensed and CE-marked for use in the market. The United States, by contrast, has fewer than 25 products approved by the FDA. The same fundamental category, injectable acid or hydroxylapatite for facial enhancement, to dramatically different degrees of evidential rigour in two of the world's most regulatory jurisdictions.

The is not a reflection of greater or a more diverse range of distinct clinical products. It is a reflection of fundamentally regulatory philosophies, and understanding those philosophies is one of the most clinically important things a practitioner in the UK aesthetic market can do.

The CE mark (Conformité Européenne) is a designation that indicates a product complies with Union safety, health, and environmental protection . For medical devices, including dermal fillers, CE under the EU Device Regulation (MDR 2017/745) means that the has been assessed for safety and performance, that the meets MDR standards, and that the product is registered in the Database on Medical Devices (EUDAMED) with a Unique Device .

What CE does not require, or has not historically required in the way that FDA approval does, is a comprehensive demonstration of through independently reviewed, conducted clinical trials. The has traditionally been conducted by third-party "notified bodies" rather than by a government regulatory agency with the power and resources of the FDA, and the bar for that a product as intended has been lower than the bar for FDA .

It is worth acknowledging that the European regulatory landscape has considerably in recent years. The new MDR 2017/745, which replaced the Device Directive, has more for clinical evidence, post-market surveillance, and . Dermal fillers are now under Annex XVI as without an medical but with significant safety implications, subject to Common Specifications that require clinical evaluation data. The direction of travel is towards greater rigour. The legacy of the old regime, a large number of that entered the market under a less demanding framework, in the number of CE-marked products currently .

The FDA classifies most dermal fillers as Class III medical devices — the highest risk classification, shared with pacemakers and implantable . This carries the most approval pathway: Pre-Market Approval (PMA), which requires the to submit clinical trial data demonstrating both the safety and the of the product for each specific use. trials to support the of a dermal filler product are reviewed and by the FDA prior to study through the Device . The FDA approves dermal fillers for specific, defined anatomic and for one area does not automatically extend to another.

The FDA's for indication-specific approval is worth particular . A product approved for nasolabial folds requires separate trial before it can be approved for lip augmentation. A for the face requires separate before it can be used on the hands. This granular, evidential requirement has no direct in the CE marking process, and it means that the supporting an FDA-approved is both more and more specifically to the situation in which it is used.

The disparity in the number of available is not primarily a of the diversity of need. Hyaluronic acid fillers, across their many branded variations, share the same of action. The clinical distinctions between products, molecular weight, degree of crosslinking, concentration, rheological properties, a relatively small number of distinct product types. The 140 CE-marked in Europe include a great many variations on established that have entered the market with limited clinical evidence their performance from existing approved products.

This is not a trivial observation. A choosing between products in the European market cannot assume that CE marking confers with FDA approval. The evidential basis for CE-marked products varies enormously, from products with extensive, conducted clinical trial data, to whose CE rests primarily on of manufacturing and .

The who assumes that any filler is as thoroughly as an one is making an that the regulatory frameworks do not support.

The consequence of this regulatory is that the burden of product falls more heavily on the practitioner in the European market than in the American one.

An practitioner choosing between FDA-approved fillers can be confident that each has a meaningful bar. A European practitioner between CE-marked products is in a market where that confidence is not and where the responsibility to the evidence behind individual products, rather than simply accepting regulatory approval as a proxy for clinical validation, is greater.

This to the problem we in an earlier piece in this series. The same critical reading skills that distinguish evidence from promotional material apply with particular force to the evaluation of filler products, who funded the studies, what the study were, whether the evidence is indication-specific, and whether independent exists.

A filler that is and manufactured to GMP standards by a reputable may still have a thinner base than its regulatory status .

The FDA's granular, approach to approval has a safety that is directly relevant to the risks we have discussed elsewhere in this blog. The FDA has additional measures into its regulatory strategy for fillers used around the Mesotherapy – Light Eyes, nose, and — areas — requiring clinical trials to and deliberately monitor for visual and to have measures in place to quickly treat subjects if vascular compromise occurs. This level of indication-specific safety scrutiny is not a standard feature of CE marking for the same products.

The FDA's adverse event for dermal fillers, the MDR database, is also a that has no direct European equivalent of scope and accessibility.

FDA event for dermal have steadily increased, with 1,478 reports in 2023, with vascular system impairment to be a common serious adverse event. The systematic collection and publication of this data allows practitioners, researchers, and to understand the safety profile of approved in a way that is harder to in the European regulatory .

It would be misleading to suggest that the is static or indifferent to these . The new MDR, fully implemented from 2021, a meaningful tightening of requirements, and the Annex XVI Common Specifications for aesthetic injectables specific clinical evidence that did not exist under the old Directive. The for post-market clinical and the obligation to register in EUDAMED represent improvements in and accountability.

The is not whether Europe is moving in the right direction; it is. The question is whether the legacy of a less demanding framework, and the 140-plus products that entered the market under it, is being with sufficient rigour and speed.

The answer, for the practitioner trying to make evidence-based product today, is that the regulatory label alone is an guide and that the habit of reading the small print, the evidence, and asking who funded the studies, is as necessary when choosing a filler as it is when evaluating any other .

The difference between 140 products and 25 ones is a difference in regulatory philosophy; in how much clinical evidence is before a reaches the market, and how specifically that must be tied to the indications for which the product will be used. That difference has implications for practitioners, for patients, and for the honest of evidence in aesthetic medicine.

A CE mark is a meaningful regulatory designation. It is not the same as FDA . Knowing the difference and the scepticism that difference warrants is part of what it means to practise evidence-based aesthetic in the European market.

The views expressed in Clinical Perspectives are the own and reflect their and professional experience in aesthetic medicine.

References

EU MDR 2017/745 Annex XVI and Common (EU) 2022/2346 for aesthetic injectables.  .

FDA Summary: General Issues Panel on Dermal . U.S. Food and Drug .2021. 

FDA Executive Summary: General Issues Panel on Dermal Fillers. U.S. Food and Drug Administration.2024. 

Regulatory Map for Dermal Fillers: US, EU, China, South Korea, Brazil. . 2026. 

CE Marked vs FDA Approved . e-Fillers. 2025. https://e-fillers.com/blog/ce-marked-vs-fda-approved-aesthetic-products

What a Toxin Scientist Taught Us About Botulinum Toxin

How Can Anti-wrinkle Injections Be The Safest Treatment in Aesthetic Medicine - And Yet Paradoxically the Most Dangerous ?

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Doctors
Company Ltd
no.

• 수정
• 삭제
• 글쓰기
• 목록